TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07216430: Safety and Efficacy of wSp Vaccine in Young Children

Sponsor: Serum Life Science Europe GmbH · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 320 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,849,800

Rescue Site Savings

+$5,174,400

Unlock Full NCT07216430 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07216430 Rescue Dossier →